A nurse is caring for a group of clients in an acute mental health facility. Which of the following clients has the legal right to refuse treatment?

Choice A reason: Electroconvulsive therapy (ECT) is reserved for severe, treatment-resistant depression or acute suicidal ideation, not general hopelessness. It involves significant risks and requires specialist oversight, making it inappropriate as a first-line intervention for this symptom, which can be addressed with less invasive methods.

Choice B reason: Cognitive behavioral therapy (CBT) targets negative thought patterns, such as hopelessness, by restructuring cognitions, a core feature of depression. Evidence-based for mood disorders, CBT reduces symptoms through structured interventions, making it the most appropriate choice for addressing hopelessness in a mental health assessment.

Choice C reason: High-dose benzodiazepines treat acute anxiety or agitation, not hopelessness, which is a depressive symptom. They risk sedation and dependence without addressing cognitive distortions, making them inappropriate for this symptom and contrary to evidence-based psychiatric nursing practice.

Choice D reason: Avoiding social interactions may worsen hopelessness by increasing isolation, a risk factor for depression. Evidence-based practice encourages social engagement to improve mood and support networks, making this intervention counterproductive and incorrect for addressing the patient’s reported symptom.

Choice A reason: Bupropion is not primarily a sedative; it is an atypical antidepressant that stimulates norepinephrine and dopamine. It may cause insomnia, not promote sleep, making this statement incorrect. Sedative medications like zolpidem are used for sleep, not bupropion, which has activating properties.

Choice B reason: Bupropion has a lower risk of sexual dysfunction compared to SSRIs, making it a suitable alternative for depression treatment in patients experiencing this side effect. Its mechanism avoids serotonin-related sexual issues, supporting its use in such cases, making this a correct choice.

Choice C reason: Bupropion is FDA-approved for major depressive disorder, acting on norepinephrine and dopamine to alleviate depressive symptoms. It is commonly prescribed for depression, making this statement true and a correct choice, as it aligns with its primary clinical use.

Choice D reason: Bupropion, under the brand Zyban, is approved for smoking cessation, as it reduces nicotine cravings and withdrawal symptoms by modulating dopamine pathways. This evidence-based use makes the statement true, correctly identifying bupropion’s role in smoking cessation programs.